U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

1998
123
Substance Class Protein
Created
by admin
on Wed Apr 02 09:43:39 GMT 2025
Edited
by admin
on Wed Apr 02 09:43:39 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin MOUSE CHIMERIC
Sequence Type COMPLETE
Record UNII
B72HH48FLU
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
INFLIXIMAB, LICENSE HOLDER UNSPECIFIED
Preferred Name English
INFLIXIMAB
EMA EPAR   HSDB   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
INFLIXIMAB [PURPLE BOOK CDER]
Common Name English
INFLIXIMAB (GENETICAL RECOMBINATION)
Common Name English
INFLIXIMAB [MART.]
Common Name English
Infliximab [WHO-DD]
Common Name English
INFLIXIMAB [HSDB]
Common Name English
IMMUNOGLOBULIN G (HUMAN-MOUSE MONOCLONAL CA2 HEAVY CHAIN ANTI-HUMAN TUMOR NECROSIS FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL CA2 LIGHT CHAIN, DIMER
Common Name English
INFLIXIMAB [VANDF]
Common Name English
INFLIXIMAB [MI]
Common Name English
TA-650
Code English
INFLIXIMAB [JAN]
Common Name English
INFLIXIMAB [EMA EPAR]
Common Name English
infliximab [INN]
Common Name English
INFLIXIMAB [USAN]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS REMSIMA (AUTHORIZED: CROHN DISEASE)
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
WHO-VATC QL04AB02
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
EMA ASSESSMENT REPORTS REMICADE (AUTHORIZED: SPONDYLITIS, ANKYLOSING)
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
NDF-RT N0000175451
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
WHO-ATC L04AB02
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
EMA ASSESSMENT REPORTS REMSIMA (AUTHORIZED: ARTHRITIS, PSORIATIC)
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
EMA ASSESSMENT REPORTS REMSIMA (AUTHORIZED: COLITIS, ULCERATIVE)
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
EMA ASSESSMENT REPORTS REMICADE (AUTHORIZED: ARTHRITIS, RHEUMATOID)
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
EMA ASSESSMENT REPORTS REMICADE (AUTHORIZED: ARTHRITIS, PSORIATIC)
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
EMA ASSESSMENT REPORTS REMICADE (AUTHORIZED: CROHN DISEASE)
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
FDA ORPHAN DRUG 168303
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
LIVERTOX NBK548203
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
FDA ORPHAN DRUG 175803
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
EMA ASSESSMENT REPORTS INFLECTRA (AUTHORIZED: CROHN DISEASE)
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
FDA ORPHAN DRUG 175903
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
EMA ASSESSMENT REPORTS INFLECTRA (AUTHORIZED: SPONDYLITIS, ANKYLOSING)
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
FDA ORPHAN DRUG 92495
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
NDF-RT N0000175610
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
FDA ORPHAN DRUG 160202
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
EMA ASSESSMENT REPORTS INFLECTRA (AUTHORIZED: COLITIS, ULCERATIVE)
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
NCI_THESAURUS C20401
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
EMA ASSESSMENT REPORTS REMICADE (AUTHORIZED: COLITIS, ULCERATIVE)
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
EMA ASSESSMENT REPORTS INFLECTRA (AUTHORIZED: ARTHRITIS, RHEUMATOID)
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
EMA ASSESSMENT REPORTS REMSIMA (AUTHORIZED: SPODYLITIS, ANKYLOSING)
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
EMA ASSESSMENT REPORTS INFLECTRA (AUTHORIZED: ARTHRITIS, PSORIATIC)
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
EMA ASSESSMENT REPORTS REMSIMA (AUTHORIZED: ARTHRITIS, RHEUMATOID)
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
FDA ORPHAN DRUG 166303
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
Code System Code Type Description
FDA UNII
B72HH48FLU
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
PRIMARY
INN
7602
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
PRIMARY
JAPANESE REVIEW
REMICADE
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
PRIMARY APPROVED AUGUST 2015
MESH
C108577
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
PRIMARY
SMS_ID
100000089417
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
PRIMARY
WIKIPEDIA
INFLIXIMAB
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
PRIMARY
RXCUI
2266523
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
ALTERNATIVE
DAILYMED
B72HH48FLU
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
PRIMARY
EVMPD
SUB02681MIG
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
PRIMARY
DRUG CENTRAL
4974
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
PRIMARY
RXCUI
191831
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
PRIMARY RxNorm
MERCK INDEX
m6284
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
PRIMARY Merck Index
USAN
II-31
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
PRIMARY
LACTMED
Infliximab
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
PRIMARY
NCI_THESAURUS
C1789
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
PRIMARY
DRUG BANK
DB00065
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201581
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
PRIMARY
RXCUI
2103476
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
ALTERNATIVE
IUPHAR
5004
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
PRIMARY
CAS
170277-31-3
Created by admin on Wed Apr 02 09:43:39 GMT 2025 , Edited by admin on Wed Apr 02 09:43:39 GMT 2025
PRIMARY
From To
1_22 1_98
2_22 2_98
2_147 2_203
2_223 4_214
2_264 2_324
1_147 1_203
2_370 2_428
3_23 3_88
3_134 3_194
4_23 4_88
4_134 4_194
1_223 3_214
1_229 2_229
1_232 2_232
1_264 1_324
1_370 1_428
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_300
N 2_300
N 3_41
N 4_41
Related Record Type Details
TUMOR NECROSIS FACTOR-.ALPHA. HUMAN (PLASMA DERIVED, SOLUBLE FORM)
TARGET -> INHIBITOR
INFLIXIMAB-QBTX
BIOSIMILAR -> PARENT
NI-071
BIOSIMILAR -> PARENT
INFLIXIMAB-AXXQ
SUB_CONCEPT->SUBSTANCE
INFLIXIMAB (REMICADE)
INNOVATOR->PARENT
INFLIXIMAB-ABDA
BIOSIMILAR -> PARENT
INFLIXIMAB (REMICADE)
SUB_CONCEPT->SUBSTANCE
BOW-015
SUB_CONCEPT->SUBSTANCE
HIGH AFFINITY IMMUNOGLOBULIN GAMMA FC RECEPTOR I
TARGET -> AGONIST
NI-071
SUB_CONCEPT->SUBSTANCE
INFLIXIMAB-ABDA
SUB_CONCEPT->SUBSTANCE
INFLIXIMAB-QBTX
SUB_CONCEPT->SUBSTANCE
INFLIXIMAB-DYYB
SUB_CONCEPT->SUBSTANCE
TUMOR NECROSIS FACTOR-.ALPHA. HUMAN (MEMBRANE BOUND FORM)
TARGET -> INHIBITOR
BINDING
INFLIXIMAB-AXXQ
BIOSIMILAR -> PARENT
Related Record Type Details
INFLIXIMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:SEQUENCE CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966